Esperion's debt financing brings in an immediate $125M, lifting the company's total pro-forma cash to $355M, and gives it flexibility going into 2020, Jefferies analyst Michael Yee tells investors in a research note. The analyst views the deal as a non-dilutive, "fundamentally good access to cash," that helps shore up Esperion's balance sheet "in case of uncertainty and macro risk in 2020." He keeps a Buy rating on the shares with an $85 price target.
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here
These names in the biotech sector are seeing a substantial increase in search activity today, as determined by InvestingChannel. They include: Altamira Therapeutics... To see the rest of the story go to thefly.com. See Story Here